Baltimore-based Paragon Bioservices, a contract research and manufacturer focused on biopharmaceuticals and vaccines, has named John Conner as senior vice president of GMP manufacturing. Previously, Conner was senior vice president of operations at CDMO Cytovance Biologics. Paragon is backed by NewSpring Capital and Camden Partners.
BALTIMORE, Nov. 22, 2016 /PRNewswire/ — A global leader in the manufacturing of biopharmaceuticals, vaccines, and viral vectors announced today the appointment of John Conner to the position of Senior Vice President of GMP Manufacturing.
“We are building a world class GMP team to complement the Company’s outstanding pre-clinical capabilities. John’s experience and leadership in growing Cytovance and expanding its service offerings to include commercial manufacturing will be invaluable in supporting Paragon’s growth initiatives in GMP vaccine and gene-therapy viral vector manufacturing,” stated Peter Buzy, President and CEO of Paragon. “John’s experience is very broad and complements well the wide array of biopharmaceuticals that we manufacture for our clients. We are excited to have John join our senior team and to be a critical part of the Company’s future growth. We look forward to his contributions as we continue to grow the company to be a world leader in vaccine, live-virus, and recombinant viral vector development and manufacturing.”
Mr. Conner is a biotechnology operation executive who has successfully led development in the areas of manufacturing, process development, analytical, manufacturing science and technology operations. He has over 30 years of experience and has spent much of his career successfully meeting the challenges of providing manufacturing services to the biotechnology industry. He was most recently the Senior Vice President of Operations at the start-up CDMO Cytovance Biologics. During his almost 11-year tenure at Cytovance, he was responsible for building the operations team, manufacturing facilities and GMP systems providing world class GMP manufacturing over several biologic platforms. Prior to Cytovance, past positions have included serving as Associate Director, Technical Support of CancerVax Corporation, where he was responsible for technology transfer and the design, construction and operation of two biologics manufacturing facilities for clinical and commercial production. In addition, he has held management positions at the John Wayne Cancer Institute and Gene Therapy Laboratories, where he managed complex immunotherapeutic and gene-therapy vector development and production. Mr. Conner earned a BS in microbiology and a graduate degree in biological sciences from the University of Texas at El Paso and Texas Tech University.
About Paragon Bioservices, Inc.
Paragon Bioservices is a private‐equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of unique biopharmaceuticals—including the production and purification of recombinant proteins, gene-therapy viral vectors such as AAV, live-virus, and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon’s 70,000 square foot cGMP facilities include microbial and mammalian suites, fill‐finish and fully‐segregated virus facilities.